Oct 13,2021

Diabetes UK's free online Type 1 and Tech Conference

It will be hosted by Prof. Partha Kar and will feature 3 of our new films. The aim of the event is to connect people living with diabetes, their parents or carers, and healthcare professionals to discover and discuss:

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 14,2021

Change in Brighter’s Board

Emilie Erhardh Winiarski today announced that she is resigning as a board member in Brighter with immediate effect. The reason is that she has taken on a new assignment which will require more of her time.

View Analyst & Ambassador Comments
Go to original news
Oct 15,2021

Observed Characteristics Associated With Diabetes Device Use Among Teens With Type 1 Diabetes

Despite advancements in diabetes technologies, disparities remain with respect to diabetes device use in youth with type 1 diabetes (T1D). We compared sociodemographic, diabetes, and psychosocial characteristics associated with device (pump and continuous glucose monitor [CGM]) use in 13- to 17-year-old teens with T1D.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 15,2021

Analysis of “Multicenter Evaluation Study Comparing a New Factory-Calibrated Real-Time Continuous Glucose Monitoring System to Existing Flash Glucose Monitoring System”

In an article in the Journal of Diabetes Science and Technology, Ji et al. report on the accuracy of a new factory calibrated continuous glucose monitoring system, the AiDEX CGM (Microtech Medical Company, Ltd., Hangzhou, China). This is the first report from a new manufacturer of a highly accurate factory calibrated CGM. The authors report that the accuracy of the AiDEX CGM is comparable to previous results from Abbott Diabetes Care and Dexcom. However, the study protocol was significantly different from previous studies. This study is the first of numerous studies likely from other manufacturers of CGM technology. It raises the question of how to evaluate sensor performance in the coming era of mass adoption of CGM and increased use of automated insulin delivery systems.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 15,2021

Costs and Outcomes Comparison of Diabetes Technology Usage Among People With Type 1 or 2 Diabetes Using Rapid-Acting Insulin

Does initiation of a continuous glucose monitor (CGM) or insulin pump lower health care utilization and/or costs?

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 17,2021

Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In silico Study

There is room for improvement in the performance of closed-loop regulation algorithms during the prandial period. This in silico study evaluated the efficiency and safety of ultrarapid lispro insulin using the Diabeloop DBLG1® algorithm.

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Oct 18,2021

Vida Health becomes the only virtual care solution with 100% fees at risk for both physical and mental health

We are excited to announce that Vida Health will be offering 100% fees at risk for both physical and mental health, becoming the first virtual care solution to do so. Vida is launching this new package, Vida Value for Body and Mind, to meet the needs of buyers seeking strong ROI and guaranteed outcomes for populations with complex cardiometabolic needs (e.g. multiple chronic conditions, co-occurring mental and physical conditions, etc.) and who are able to share claims data to measure this impact.

PRODUCT

#virtual care

View Analyst & Ambassador Comments
Go to original news
Oct 18,2021

Voluntis announces the success of the Tender Offer initiated by the Aptar company allowing the implementation of mandatory squeeze-out

Voluntis, a leader in the field of digital therapeutics, announces the successful completion of the Simplified Tender Offer (“the Offer“) initiated by AptarGroup, Inc. (“Aptar” – NYSE: ATR) to acquire the shares of Voluntis. As a result of the Offer, Aptar has exceeded the threshold of 90% of the share capital and theoretical voting rights of Voluntis and will therefore file a request with the AMF for the implementation of a squeeze-out of the Voluntis shares not tendered to the Offer followed by the delisting of the Company’s shares from Euronext Growth. The notice of the result of the Offer was published today by the French Markets Authority (AMF).

View Analyst & Ambassador Comments
Go to original news
Oct 18,2021

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Luciana Borio, M.D., has been appointed to the Company’s Board of Directors.

View Analyst & Ambassador Comments
Go to original news
Oct 19,2021

Children achieve Time in Range mirroring well-controlled adults for the first time in real-world study of the MiniMed™ 780G system

Harder to manage pediatric and adolescent patients achieve 74% Time in Range, and 82% overnight Time in Range, well surpassing clinical consensus guidelines for glycemic control DUBLIN, Oct. 19,...

CLINICAL STUDY

#closed loop

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES